Table 2 Baseline characteristics and mortality of norepinephrine- vs. vasopressin-treated patients in SPH1 before and after matching. Sensitivity analysis after exclusion of patients who had underlying NYHA IV CHF
Variable | Norepinephrine | Vasopressin | p |
|---|---|---|---|
Baseline characteristics norepinephrine- vs. vasopressin-treated patients in SPH1 before matching | |||
Age (years), X ± SD | 60.2 ± 16.3 | 55.5 ± 15.5 | < 0.001 |
APACHE II, X ± SD | 25.5 ± 8.0 | 29.0 ± 8.7 | < 0.001 |
Gender (% male) | 61.3 | 73.1 | 0.009 |
Surgical (%) | 28.2 | 31.0 | 0.503 |
Respiratory (%) | 88.6 | 92.4 | 0.183 |
Renal (%) | 68.4 | 82.8 | < 0.001 |
Coagulation (%) | 23.4 | 38.0 | < 0.001 |
Hepatic (%) | 13.9 | 22.8 | 0.01 |
Neurological (%) | 64.8 | 80.0 | < 0.001 |
Ventilated (%) | 92.4 | 89.0 | 0.188 |
Any chronic disease (%) | 41.3 | 49.7 | 0.073 |
Norepinephrine dose (ug/min) | 13.6 ± 15.0 | 21.8 ± 22.0 | < 0.001 |
Baseline characteristics norepinephrine- vs. vasopressin-treated patients in SPH1 after matching | |||
Age (years), X ± SD | 56.8 ± 14.9 | 56.1 ± 15.3 | 0.644 |
APACHE II, X ± SD | 28.5 ± 8.2 | 28.8 ± 8.4 | 0.831 |
Gender (% male) | 66.4 | 72.9 | 0.242 |
Surgical (%) | 31.4 | 31.4 | 1 |
Respiratory (%) | 92.9 | 92.1 | 0.821 |
Renal (%) | 77.1 | 82.1 | 0.299 |
Coagulation (%) | 28.6 | 37.9 | 0.099 |
Hepatic (%) | 18.6 | 23.6 | 0.305 |
Neurological (%) | 71.4 | 79.3 | 0.127 |
Ventilated (%) | 93.6 | 89.3 | 0.2 |
Any chronic disease (%) | 47.9 | 48.6 | 0.905 |
Mortality of norepinephrine- vs. vasopressin-treated patients in SPH1 after matching | |||
28-day mortality (%) | 46.4 | 62.9 | 0.006 |